Mangoceuticals terminates Diabetinol licensing deal; cancels 1M shares issued to Navy Wharf

MANGOCEUTICALS, INC.

Mutually rescinded March 2025 Master Distribution Agreement for Diabetinol, effective July 30, 2025.
No material early termination penalties incurred by Mangoceuticals.
Navy Wharf agreed to cancel all 1,000,000 previously issued restricted shares as consideration.
Unrelated: warrant holder exercised 198,000 warrants at $1.50, raising $297,000 for the company.

item 1.01item 1.02item 2.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.